Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye drops could lift droopy eyelids without surgery

NCT ID NCT06683651

Symptom relief Sponsor: Santen Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new eye drop (STN1013800) for adults with acquired droopy eyelids, a condition that can block vision. About 180 Chinese participants will receive either the eye drop or a placebo once daily for 42 days. The goal is to see if the drops improve vision by lifting the eyelid, offering a non-surgical option.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * At least one eye diagnosed with acquired blepharoptosis and presence of all the following criteria at screening: * Loss of reliable Leicester Peripheral Field Test (LPFT) of ≥ 8 points in the top 2 rows (LPFT Eligibility Score); subjects had to see at least 9 total points in the top 4 rows (LPFT Total Score). * This criterion had to be met in both the Visit 1 Hour 0 (V1H0) and Visit 1 Hour 6 (V1H6) LPFT assessments. * There had to be ≤4 points of variance between the V1H0 and the V1H6 LPFT Eligibility Score. * The Marginal Reflex Distance-1 (MRD-1), the distance from the pupil center to the margin of upper lid, ≤ 2 mm (no visible pupil center defaults to 0) in the same eye * Visual acuity is 0.25 decimals (i.e., Snellen 20/80) or better according to standard logarithmic visual acuity chart in the same eye * Presence of all the following criteria at baseline: * Loss of reliable LPFT of ≥8 points in the top 2 rows (LPFT Eligibility Score) in the same eye; subjects had to see at least 9 total points in the top 4 rows (LPFT Total Score). * This criterion had to be met in the Visit 2 Hour 0 (V2H0) LPFT assessment * There had to be ≤4 points of variance between the V1H6 and the V2H0 LPFT Eligibility Score; * The MRD-1, the distance from the pupil center to the margin of upper lid, ≤ 2 mm (no visible pupil center defaults to 0) in the same eye * Visual acuity is 0.25 decimals (i.e., Snellen 20/80) or better according to standard logarithmic visual acuity chart in the same eye * Female subjects are 1-year postmenopausal, surgically sterilized, or females of childbearing potential (females who had started their menstrual cycles) with a negative urine pregnancy test at screening. Females of childbearing potential had to use an acceptable form of contraception throughout the study. Exclusion Criteria: In the study eye * Dermatochalasis that extended less than 3 mm above the upper eyelid margin. * Pseudoptosis (upper eyelid dermatochalasis that overhung the upper eyelid margin). * In either eye: Congenital ptosis; Horner syndrome; Marcus Gunn jaw-winking syndrome; Myasthenia gravis. * Mechanical ptosis, including ptosis due to orbital or lid tumour, cicatricial processes affecting the movements of the upper lid, and enophthalmos. * Previous ptosis surgery (previous blepharoplasty \[only\] was allowed provided the surgery took place \> 3 months prior to screening). * Lid position affected by lid or conjunctival scarring; Visual field loss from any cause other than ptosis; History of herpes keratitis. * History of closed/narrow angle glaucoma (unless patent peripheral iridotomy had been performed \> 3 months prior to screening). * Periocular neurotoxin (e.g., Botox®, Dysport®) injections within 3 months prior to screening and during the study. * Topical application of bimatoprost (i.e., Latisse®) to the eyelashes within 7 days prior to screening and during the study. * Use of topical ophthalmic medications including but not limited to anti-allergy \[e.g., antihistamines like Emadine®, Patanol®\], dry eye \[e.g., Diquas®, Beifushu®; except artificial tears like Hyaluronate\], antimicrobial drugs \[e.g., antibiotics and antivirals like Cravit®,Tobrex®, Aciclovir\], and anti-inflammatory drugs * Current punctal plugs or placement of punctal plugs during the study. * Current use of over-the-counter (OTC) vasoconstrictor/decongestant eye medication or any ophthalmic or non-ophthalmic α-adrenergic agonist including OTC products at any time during the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Blepharoptosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ptosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Blepharoptosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    23 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Affiliated Hospital of Guizhou Medical University

    RECRUITING

    Guiyang, Guizhou, China

  • Anhui Provincial Hospital

    RECRUITING

    Hefei, Anhui, China

  • Beijing Chaoyang Hospital, Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, China

  • Beijing Luhe Hospital, Capital Medical University

    RECRUITING

    Beijing, China

  • Dalian No.3 Peple's Hospital

    RECRUITING

    Dali, Liaoning, China

  • Eye & Ent Hospital of Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, China

  • Eye Hospital, Wenzhou Medical University / Zhejiang Eye Hospital

    RECRUITING

    Wenzhou, Zhejiang, China

  • Joint Shantou International Eye Center of Shantou University and the Chinese University of Hong Kong

    RECRUITING

    Shantou, Guangdong, China

  • Nanjing First Hospital

    RECRUITING

    Nanjing, Jiangsu, China

  • Panzhihua Hospital of Integrated Chinese and Western Medicine

    RECRUITING

    Panzhihua, Sichuan, China

  • Shandong Eye Hospital

    RECRUITING

    Jinan, Shandong, China

  • Shanxi Eye Hospital

    RECRUITING

    Taiyuan, Shanxi, China

  • Sir Run Run Shaw Hospital (SRRSH), affiliated with the Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, China

  • The 2nd Affiliated Hospital of Harbin Medical University

    RECRUITING

    Ha’erbin, Helongjiang, China

  • The 4TH People's Hospital of Shenyang

    RECRUITING

    Shenyang, Liaoning, China

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, China

  • The Second Hospital of Anhui Medical University

    RECRUITING

    Hefei, Anhui, China

  • The affiliated People's Hospital of Ningbo

    RECRUITING

    Zhenjiang, Ningbo, China

  • The first affiliated hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, He'nan, China

  • The second norman bethune hospital of Jilin University

    RECRUITING

    Changchun, Jilin, China

  • Tianjin Eye Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, China

  • Wuhan Aier Eye Hospital

    RECRUITING

    Wuhan, Hubei, China

  • Xiangyang Central Hospital

    RECRUITING

    Xiangyang, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.